Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Peficitinib (ASP015K) in RA Patients with Inadequate Response to DMARDs
NCT02308163Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Aug 2014
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of peficitinib in rheumatoid arthritis (RA), sponsored by Astellas Pharma. Started Aug 2014; status: completed.
02
Drugs
peficitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02308163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02308163.